In a murine sarcoma model lacking mouse MHC and transgenic for human MHC class I and II, vaccination with IDH1R132H p123–142 resulted in robust interferon (IFN)-γ mutation-specific T-cell responses that were effective in control growth of syngeneic IDH1(R132H)-expressing tumors [33] (Table 1). The gene discussed is HLA-C; the disease is sarcoma.